News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma

Al's Comment:

 I was really hoping this trial would turn out well but it failed to meet it's endpoints.   This is a different way of using vaccines - it makes a lot of sense.  However, they chose to try it on recurrent glioblastomas, which might have been too late. 


Posted on: 03/12/2019

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740